Skip to main content
Sansure Biotech Inc. logo

Sansure Biotech Inc. — Investor Relations & Filings

Ticker · 688289 ISIN · CNE1000043J1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 870 across all filing types
Latest filing 2025-05-12 AGM Information
Country CN China
Listing Shanghai Stock Exchange 688289

About Sansure Biotech Inc.

https://www.sansureglobal.com/

Sansure Biotech Inc. specializes in the development and manufacture of molecular diagnostic products and genetic testing solutions. The company utilizes proprietary technologies, such as the "One-tube" fast extraction method and advanced magnetic bead technology, to provide high-sensitivity PCR diagnostic kits. Its product portfolio covers a wide range of clinical applications, including infectious disease screening for hepatitis, respiratory infections, and sexually transmitted infections, as well as oncology and maternal health. Sansure also provides integrated laboratory automation systems, including nucleic acid extractors and real-time PCR instruments, designed to streamline clinical workflows and improve diagnostic efficiency for healthcare providers and research institutions globally.

Recent filings

Filing Released Lang Actions
圣湘生物科技股份有限公司2024年年度股东大会会议资料
AGM Information Classification · 100% confidence The document is titled as "2024 年年度股东大会会议资料" which translates to "2024 Annual General Meeting (AGM) Meeting Materials" for 圣湘生物科技股份有限公司. It contains detailed agenda items, reports, proposals, and instructions related to the 2024 Annual General Meeting scheduled for May 20, 2025. The content includes the board work report, annual report summary, remuneration proposals, profit distribution plans, auditor appointments, and supervisory board reports, all typical materials prepared and distributed for an AGM. The document is lengthy (15,000 characters) and contains the actual meeting materials, not just an announcement or a brief summary. Therefore, it fits the category of AGM Information (AGM-R).
2025-05-12 Chinese
圣湘生物科技股份有限公司第二届监事会2025年第四次临时会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of a resolution passed at a supervisory board meeting (监事会会议决议公告) regarding an investment decision. It includes details about the meeting date, attendance, the resolution content, and voting results. It references another announcement for more details. The document is short (740 characters) and is an official meeting resolution announcement rather than a full report or financial statement. It does not contain financial data or detailed management discussion. It is not an Annual Report, Interim Report, or Earnings Release. It is not a Board/Management change announcement but a supervisory board meeting resolution. The best fitting category is Regulatory Filings (RNS) as it is a regulatory announcement of a board meeting resolution that does not fit other specific categories.
2025-05-08 Chinese
圣湘生物科技股份有限公司关于增资湖南圣维鲲腾生物科技有限公司暨与关联方共同投资的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement about a capital increase investment by 圣湘生物科技股份有限公司 into 湖南圣维鲲腾生物科技有限公司, including specifics on the investment amounts, shareholder structure before and after the transaction, related party involvement, approvals by the board and supervisory committees, and risk disclosures. It discusses the transaction terms, pricing, and the strategic rationale behind the investment. The document is not a financial report, earnings release, or audit report, but rather a formal announcement of a financing activity involving capital injection and equity changes. It is not a brief notice but a comprehensive disclosure of a capital/financing update. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2025-05-08 Chinese
圣湘生物科技股份有限公司关于2024年年度股东大会增加临时提案的公告
AGM Information Classification · 95% confidence The document is a detailed announcement regarding the addition of a temporary proposal to the 2024 Annual General Meeting (AGM) of 圣湘生物科技股份有限公司. It includes information about the AGM date, shareholder registration date, proposal details, voting procedures, and proxy forms. The content focuses on the AGM logistics and agenda items rather than the full annual report or financial statements. The document is about the AGM meeting and related materials, not the report itself or voting results. Therefore, it fits the category of AGM Information (AGM-R). The document length is under 5,000 characters but contains substantive AGM-related content, not just a brief announcement or report publication notice.
2025-05-08 Chinese
圣湘生物科技股份有限公司关于聘任公司2025年度财务审计机构及内控审计机构的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the appointment of the company's financial audit and internal control audit institutions for the year 2025. It details the qualifications, background, and integrity of the proposed audit firm, the procedures followed for the appointment, and the approval process by the audit committee and board of directors. It does not contain actual financial statements or audit results but is a formal announcement about the appointment of auditors for the upcoming fiscal year. The document length is 2517 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this document fits best under the category of Audit Report / Information (AR), as it relates to audit information but is not a full annual report or audit report itself. However, since it is specifically about the appointment of the audit firm and related audit information, AR is the most appropriate classification. FY 2025
2025-04-28 Chinese
圣湘生物科技股份有限公司2024年度独立董事述职报告（王善平）
Board/Management Information Classification · 95% confidence The document is titled as the "2024年度独立董事述职报告" which translates to "2024 Annual Independent Director's Work Report." It is a detailed report by an independent director about their duties, attendance, communication with shareholders, oversight of financial reporting, internal controls, audit firm engagement, and governance activities during the year 2024. The content focuses on the independent director's role, their evaluation of company governance, financial reporting integrity, and recommendations for the future. It is not an announcement of a report, nor a certification or a brief summary. It is a management-related report focusing on governance and oversight by the independent director, which fits best under the category of Board/Management Information (MANG). The document is about the independent director's duties and activities, which is a form of management information rather than a full annual report or audit report. Therefore, the classification is MANG with high confidence.
2025-04-28 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.